DRTS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.124

-4.99%

-0.120

-0%

-0.120

-7.69%

Estimates Revision

The market is revising No Change the revenue expectations for Alpha Tau Medical Ltd. (DRTS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 65.63%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+11.02%

In Past 3 Month

Stock Price

Go Up

+65.63%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast DRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

5.00

Averages

7.00

High

9.00

Current: 0.000

Low

5.00

Averages

7.00

High

9.00

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

2025-03-17

Reason

HC Wainwright & Co.

Yi Chen

Price Target

2025-03-17

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Alpha Tau Medical Ltd (DRTS.O) is -9.99, compared to its 5-year average forward P/E of -13.03. For a more detailed relative valuation and DCF analysis to assess Alpha Tau Medical Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-13.03

Current PE

-9.99

Overvalued PE

-1.42

Undervalued PE

-24.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.56

Current EV/EBITDA

-8.46

Overvalued EV/EBITDA

-0.17

Undervalued EV/EBITDA

-8.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

405.14

Current PS

652.66

Overvalued PS

1128.89

Undervalued PS

-318.62

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DRTS News & Events

Events Timeline

No data

News

9.0

01-06NASDAQ.COM

Alpha Tau Medical Submits FDA Application for Alpha DaRT Therapy

2.0

01-06NASDAQ.COM

Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement

1.0

2025-12-18Newsfilter

Alpha Tau Medical to Present Alpha DaRT® Progress at J.P. Morgan Healthcare Conference

People Also Watch

Frequently Asked Questions

What is Alpha Tau Medical Ltd (DRTS) stock price today?

The current price of DRTS is 6.41 USD — it has increased 8.64 % in the last trading day.

What is Alpha Tau Medical Ltd (DRTS)'s business?

Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.

What is the price predicton of DRTS Stock?

What is Alpha Tau Medical Ltd (DRTS)'s revenue for the last quarter?

Alpha Tau Medical Ltd revenue for the last quarter amounts to -10.73M USD, increased 29.43 % YoY.

What is Alpha Tau Medical Ltd (DRTS)'s earnings per share (EPS) for the last quarter?

Alpha Tau Medical Ltd. EPS for the last quarter amounts to -9120000.00 USD, increased 221.47 % YoY.

What changes have occurred in the market's expectations for Alpha Tau Medical Ltd (DRTS)'s fundamentals?

How many employees does Alpha Tau Medical Ltd (DRTS). have?

Alpha Tau Medical Ltd (DRTS) has 125 emplpoyees as of January 09 2026.

What is Alpha Tau Medical Ltd (DRTS) market cap?

Today DRTS has the market capitalization of 546.54M USD.